非小细胞肺癌中RET融合基因的研究进展
| 作者: |
1方霆,
1李代强
1 中南大学湘雅二医院病理科，长沙 410011 |
| 通讯: |
方霆
Email: lilill1229@sina.com 李代强 Email: lidqxf@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2015.02.026 |
摘要
存在于1%~2%的非小细胞肺癌患者中的RET融合基因具有鲜明的临床病理学特征，且RET抑制剂 对其治疗有效，提示RET融合基因已成为该类患者个体化分子靶向治疗的新靶点。本文将对RET 融合基因的特点及其在非小细胞肺癌(non-small cell lung cancer，NSCLC)患者中的表达和治疗的研 究进展进行阐述。
关键词：
RET融合基因
非小细胞肺癌
靶向治疗
Research progress of RET fusion gene in non-small cell lung cancer
CorrespondingAuthor: FANG Ting Email: lilill1229@sina.com
DOI: 10.3978/j.issn.2095-6959.2015.02.026
Abstract
RET fusion gene with an identifiable clinicopathological characteristics, is present in 1% to 2% of non-small cell lung cancer patients, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene is a new target for individualized treatment to the patients of NSCLC. This article reviews the characteristics of RET fusion gene and expression patterns in patients, and treatment of NSCLC.